Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant

Recruiting now · Not applicable

Conditions studied: Chronic Liver Disease

In brief

Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia reperfusion injury, recipient metabolic demand, graft quality, graft inflow and outflow. Studies shows that the incidence of EGD is 15-38%. It is associated with increased allograft loss \& mortality. Rifaximin is an antibiotic that reduces EGD by 50% as shown by 2 studies but this study was done in DDLT setting and rifaximin was given in the pretransplant group. In this investigators will study the effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant.

Key facts

Study ID

NCT06743464

Run by

Institute of Liver and Biliary Sciences, India

People needed

100

Starts

2024-12-01

Expected to finish

2025-12-31

Last updated by the study team

2025-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All recipients (adults) undergoing living donor liver transplant in ILBS.

You may not qualify if…

• Negative consent
• Hypersensitivity to Rifaximin
• Patients undergoing retransplant
• ALF, ACLF
• Pediatrics patients
• Patients on rifaximin

Where it is running

• Insitute of Liver and Biliary Sciences — New Delhi, National Capital Territory of Delhi, India (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.